Moreover, the recipient mice administered with the α-galactosyl ceramide derivative RGI-2001 at transplantation improves GVHD by expanding donor-derived CD4+ Foxp3+ Tregs in the bone marrow and secondary lymphoid organs in a dose-dependent manner (52). Here, CD4 is linked to graft versus host disease.